Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2022-09-19 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团独立董事关于公司十届八次董事会相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from the independent directors of Kunming Pharmaceutical Group Co., Ltd. regarding several board resolutions, including the use of idle raised funds for cash management, investment of idle funds, asset pledge financing, and repurchase and cancellation of restricted stock related to a stock incentive plan. The document references compliance with stock exchange rules and company articles but does not contain financial statements or detailed financial data. It is a formal opinion on board matters rather than a full report or announcement of voting results. The document length is short (1339 characters), and it is not a report publication announcement or certification. The content fits best under Board/Management Information (MANG) as it relates to board decisions and independent directors' opinions on company governance matters.
2022-09-19 Chinese
昆药集团关于利用闲置自有资金进行投资理财业务的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the use of idle funds for investment in financial products. It includes details about the investment purpose, authorization limits, risk analysis, and opinions from independent directors and the supervisory board. The document is a formal announcement of a corporate decision pending shareholder approval, not a financial report or earnings release. It does not contain financial statements or detailed financial data. The content fits the category of a Capital/Financing Update as it relates to the company's capital management and investment activities.
2022-09-19 Chinese
昆药集团关于以票据、应收账款、理财产品等资产质押开展融资类业务的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the company's plan to use assets such as bank acceptance bills, accounts receivable, and financial products as collateral to conduct financing activities. It details the business overview, specific plan, purpose, risk and mitigation measures, decision procedures, and independent director opinions. The document is relatively short (1501 characters) and focuses on financing activities and asset pledging. It does not contain financial statements or detailed financial results, nor is it a report or transcript. It is clearly an update on financing activities, specifically asset-backed financing. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-09-19 Chinese
昆药集团关于召开公司2022年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2022 first extraordinary general meeting of shareholders for Kunming Pharmaceutical Group Co., Ltd. It includes details about the meeting date, voting methods, agenda items, and proxy authorization. It does not contain financial statements or results but is an announcement related to a shareholder meeting. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting and voting procedures rather than the solicitation materials or voting results, it aligns best with Proxy Solicitation & Information Statement (PSI). The document length is 3011 characters, which is short and typical for a meeting notice. Therefore, the classification is PSI with high confidence.
2022-09-19 Chinese
昆药集团十届八次监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed by the Supervisory Board (监事会) of Kunming Pharmaceutical Group Co., Ltd. It details decisions on various financial and operational matters such as the use of idle raised funds for cash management, investment of idle funds, foreign exchange hedging, asset pledge financing, and repurchase and cancellation of restricted stock. The document includes voting results and supervisory board opinions, indicating it is a meeting resolution announcement. It does not contain full financial statements or detailed financial performance data, nor is it a transcript or presentation. The document is relatively short (1521 characters) and is an official announcement of board resolutions rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and compliance documents that do not fit other specific categories.
2022-09-19 Chinese
昆药集团十届八次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 8th meeting of the 10th Board of Directors of Kunming Pharmaceutical Group Co., Ltd. It details voting results on various proposals such as use of idle funds, foreign exchange hedging, financing business, stock repurchase, subsidiary cancellation, and convening an extraordinary general meeting. The content focuses on board decisions and approvals, with no financial statements or earnings data. It is not a full annual or interim report, nor an earnings release or audit report. The document is a board meeting resolution announcement, fitting the Board/Management Information (MANG) category.
2022-09-19 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.